Original Research Article

Finding the Incidence of Ventilator Associated Pneumonia by Recent NHSN Guidelines and Its Bacteriological Profile: A Study Conducted in a Tertiary Care Hospital in Southern India

Sadiya Fatima¹*, S. Rajeshwar Rao², V.V. Shailaja³ and K. Nagamani⁴

Department of Microbiology, Gandhi Medical College and Hospital, Secunderabad, Telangana, India

*Corresponding author

Abstract

Ventilator associated pneumonia is the second most common nosocomial infection in the intensive care unit (ICU) and the most common in mechanically ventilated patients. The present study was undertaken to elucidate the bacteriological profile causing VAP in our institution and finding its incidence by recent NHSN guidelines. Study was conducted for 1 year study period (June 2017 - May 2018). All the patients were monitored from the time of inclusion in the study for the entire duration of the hospital stay. Relevant details of the patients were included in the study in a structured proforma and surveyed for possible VAP as per the recent NHSN guidelines. Gram stain and semi-quantitative cultures of Purulent Endotracheal aspirates of patients were processed as per standard protocols. The clinical isolates obtained were identified by both conventional and automated methods. Among 104 patients 31 developed PVAP (possible VAP) during their ICU stay; of these two patients had 2 episodes of VAP each, incidence of VAP was 32%. The overall incidence rate was 38.42 /1000VD. Most common isolate was Acinetobacter baumanii (38%) followed by Pseudomonas aeruginosa (22%), Klebsiella pneumoniae (16%) and Escherichia coli (13.51%). The overall mortality was 48.38%. There is a need for compilation of local epidemiological data at all centers, as such information can help in guiding the initial empirical therapy which would reduce the ICU stay thereby the rate of VAP.

Keywords

Intensive care unit, Mechanical ventilation (MV), Ventilator associated event, Ventilator associated pneumonia

Article Info

Accepted: 15 September 2019
Available Online: 10 October 2019

Introduction

Ventilator associated pneumonia refers to bacterial pneumonia developed in patients who have been mechanically ventilated for a duration of more than 48 hrs.¹ It is the second most common nosocomial infection in the intensive care unit (ICU) and the most common in mechanically ventilated patients. The incidence of VAP ranges from 13 to 51 per 1000 ventilator days.² The incidence of VAP varies among different studies, depending on the definition, the type of hospital or ICU, the population studied, and the level of antibiotic exposure.³ The causative
organisms vary according to the patients demographics in the ICU, the duration of hospital/ICU stay, and the antibiotic policy of the institution.

The study was conducted to find the incidence of PVAP by using the recent definition guidelines and to elucidate bacteriological profile of VAP among mechanically ventilated patients admitted in RICU department of Gandhi Hospital. *Acinetobacter* spp., *Pseudomonas* spp., *Escherichia coli*, *Klebsiella pneumoniae*, and *Staphylococcus aureus* were identified as the common VAP pathogens.

Although mechanical ventilation (MV) is a life-saving intervention, it has its own potential complications. VAP occurrence is increased with prolonged length of ICU stay. A method to reduce the risk of VAP is to extubate patients as soon as possible as various randomized, and observational studies have shown that the risk of developing VAP increases with the duration of an endotracheal tube remaining in place. The use of appropriate weaning protocols and the regular assessment of sedation requirements are effective in reducing the duration of MV and hence the incidence of VAP.

**Materials and Methods**

**Setting and subjects**

The prospective study was conducted over a period of 1 year from June-2017 to May 2018 of all mechanically ventilated patients admitted in RICU of Gandhi medical college and hospital a tertiary care hospital in Telangana, India.

An ethical clearance to conduct this study was obtained from institutional ethical committee prior to commencement of the study.

The subjects consisted of all adult patients (>18yrs) presented with acute respiratory failure due to a variety of causes and required mechanical ventilation for >48 hours.

Patients not admitted in RICU (Respiratory Intensive care units) i.e. admitted in general wards, other ICU’s or treated in other departments, Patients with pneumonia prior to MV or within 48 hours of MV and Patients on high frequency ventilation or extracorporeal life support or brain dead, Lung expansion devices such as intermittent positive-pressure breathing (IPPB), Nasal positive end-expiratory pressure (nasal PEEP), Continuous nasal positive airway pressure (CPAP, hypo CPAP) were excluded.

**Study design and data collection**

All the relevant details of the patients included in the study, i.e. name, age, sex, occupation, diagnosis, duration of illness, reason for mechanical intubation, whether any surgical intervention done, history of antibiotic usage, site of infection, past history, family history, were taken in a structured proforma.

**Procedure for data collection**

All patients included in the study were monitored daily for the development of VAP using recent CDC NHSN clinical and microbiological criteria until either discharge or death.

The clinical parameters were recorded from their medical records and bedside charts. Details of antibiotic therapy, surgery, use of steroids, duration of hospitalization, presence of neurological disorders, and impairment of consciousness were also noted.

**Criteria for diagnosis of VAP**

Oxygen demand on ventilator was measured by fraction of inspired oxygen (FiO2) or positive end-expiratory pressure (PEEP).
Criteria for defining VAC

Ventilator associated condition is defined as worsening of oxygenation sustained for at least 2 CL immediately after the baseline period of stability or improvement of 2 days.

Worsening of oxygenation defined as

- FiO2: ↑ in daily minimum FiO2 of ≥0.20 (20%) after 2 calendar days of stability (OR)
- PEEP: ↑ in the daily minimum PEEP of ≥3 cm H2O after 2 calendar days of stability (PEEP values of 0 cm-5 cm H2O are considered equivalent)

Criteria for defining IVAC

Both of the criteria must occur in the VAE window period

- Presence of temperature >38°C or <36°C or WBC ≥12,000 cells/mm3 or ≤4000 cells/mm3
- A new antimicrobial agent (s)* is started and continued for ≥4 calendar days in a mechanically ventilated patient on or after calendar day 3

Criteria for defining Possible VAP (PVAP) as microbiological evidence of infection in patient with IVAC.

- Culture without sufficient growth having Purulent respiratory secretions (>25 neutrophils and <10 squamous epithelial cells per low power field)

Microbiological techniques

Specimen collection

Endotracheal aspirate (ETA) was chosen as sample because it is non-invasive and was proved to give similar results when compared with invasive procedures like PSB (Protected specimen brush), BAL (Broncho alveolar lavage). The ETA was collected under aseptic precaution in the patient qualifying IVAC criteria using a 22-inch Ramson's 12 F suction catheter with a mucus extractor (Lukens trap shown in the figure 1), which was gently introduced through the endotracheal tube for a distance of approximately 25-26 cm.

Specimen processing

Specimen was immediately processed after collection. Gram stain of the sample was done.

To consider it as a purulent sample, Gram stain should show: >25 PMN neutrophils/LPF and <10 squamous epithelial cells. One of those purulent gram stain is shown in figure 2. Semi-Quantitative cultures were done by serial dilution in sterile normal saline as 1/10, 1/100, 1/1000, and 0.01 ml of 1/1,000 dilution was inoculated on 5% sheep blood agar, Chocolate agar, MacConkey agar and Sabourad’s Dextrose agar. Inoculated plates were incubated at 37°C for 18-24 hrs.
plates were checked for growth overnight and then after 24-48 hr of incubation. SDA slants were checked up for 4 weeks. Colony count was done and expressed as number of colony forming units per ml (CFU/ml). The microorganisms isolated at a concentration of more than $10^5$ CFU/ml were considered as significant and also if the colony count is less than purulent gram stain was taken into consideration and colonies were identified based on standard bacteriological procedures including colony morphology and biochemical reactions\(^\text{10}\). Subsequently, further confirmation of identification was done by automated Vitek2 system.

**Results and Discussion**

Over the 1 year study period (June 2017 to May 2018) 204 patients were admitted in the respiratory intensive care unit were prospectively evaluated. Of these 28 patients (13.72\%) were not intubated, as there were no indications for mechanical ventilation.

Among those requiring MV, 72 (35.29\%) patients were mechanically ventilated for less than 48 hours therefore excluded from the study.

**Incidence**

104 (50.98\%) patients received mechanical ventilation for more than 48 hours and were monitored daily. Of these 104 patients, 31 (15.19\%) patients developed VAP during their ICU stay. 2 patients had 2 episodes of VAP each. Incidence of VAP was 31.73\% as shown in Table 1.

Formula to calculate VAP rate:

\[
\text{Rate} = \frac{\text{VAP Episodes}}{\text{Total VD}} \times 1000
\]

The overall incidence rate was 38.42 per 1000 ventilator days.

VAE was more in the patients staying for more than 10 days and it was less when the duration of mechanical ventilation was less. Number of patients was more in <5 days MV but the development of VAP was less though VAC was there. Patients on MV for >15 days were less but most of them developed VAP signifying the role of duration of MV for VAP.

The incidence of VAP was more common in males (71\%) than females (29\%) as shown in figure 3. Male sex was found to be one of the non-modifiable patient-related risk factor for the development of VAP.

**Organism-wise distribution of VAP**

*Acinetobacter* spp was the most common organism (37.83\%) among which *Acinetobacter baumanii* was more common than *A. lowii*, *Pseudomonas* spp (21.62\%) were the second most common organism followed by *Klebsiella* spp (16.21\%), *Escherichia coli* (13.51\%) while *Elizabethkingia meningoseptica* and *Enterobacter cloacae* were the least common one among gram negative organisms being only one isolate (2.70\%) each. The 2 isolates of *Staphylococcus aureus* accounting for (5.40\%) were the only gram positive organism identified. No fungal isolate found in any of the sample tested (Fig. 4 and Table 2).

**Outcome**

In this study the crude mortality rate of patients with VAP was 48.38\%.

Novelty of our work comes from being the first to study VAP according to newer NHSN guidelines in Telangana by taking into consideration clinical, radiological and microbiological results together. VAP accounts for one-fourth of the infections
occurring in critically ill patients and is the reason for half of antibiotic prescriptions in mechanically ventilated patients. Several countries have reported mortality rates ranging from 24% to 76% (Table 3).

**Fig.1** Lukens trap

**Fig.2** Direct Gram’s stain smear showing plenty of polymorphonuclear leucocytes
Table.1 Incidence of VAP

| Episodes of VAP | Patients | Total Patients |
|----------------|----------|----------------|
| 33             | 31       | 104            |

Table.2 Overall VAP Rate

| VAP | Total Ventilator Days | Rate (Per 1000 VDs) |
|-----|-----------------------|---------------------|
| 33  | 859                   | 38.416              |

Table.3 Correlation between ventilator days and development of ventilator-associated events

| VAE                                      | Ventilator days (VDs) |
|------------------------------------------|-----------------------|
|                                          | ≤ 5 days | 6-10 days | 11-14 days | >15 days |
| Number of patients on MV                 | 43       | 34        | 11         | 16       |
| Episodes of VAC only                     | 13       | 19        | 10         | 12       |
| Episodes of IVAC                         | 07       | 08        | 10         | 10       |
| Episodes of PVAP                         | 04       | 08        | 10         | 11       |
| Episodes of PVAP per number of patients  | 9.30%    | 23.53%    | 90.9%      | 68.75%   |

Fig.3 Male and Female distribution in VAP cases

2085
In the present study, the incidence rate of VAP was 31.73% correlating with studies from Odisha by Mohanty, et al., (2016) who reported as 30%, from UP by Alok Gupta et al., (2011) who reported as 28.04%, from Saudi Arabia by Abdelrazik Othman et al., (2017) who reported as 35.4%. While a study from MP by Ranjan et al., (2014) reported 57.14% and from Maharashtra by Deshmukh B et al., (2017) reported 78%. Divergence of incidence can be attributed to several factors such as differences in the study population, differences in the definition of VAP, e.g. depending on the diagnostic criteria used, clinically versus microbiologically oriented and possibly, to the use of preventive strategies and critical care practices in the ICUs.

Sex distribution in VAP cases in our study was found to be 70.96% among males and females constituted 29.03%. Vinigtarg et al., in 2017 reported male predominance around 68.3% and Saroj Golia et al., in 2013 also found incidence of VAP is more in men (65.4%) than females (34.61%). Usman et al., (2014) also reported male dominance (65%) in his study.

Acinetobactersps followed by Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae were common organisms isolated in this study. The organisms implicated in VAP were similar in other studies such as Dube et al., (2018), Maqbool et al., (2017), Mathai et al., (2016) and Ranjan et al., (2014) with Acinetobactersps as the most
common organism isolated. In contrast Deshmukh et al., Masih et al., (2016) and Husain Shabbir Ali et al., (2016) reported Pseudomonas aeruginosa as the most common organism.

In our study mortality was 48.38% and it is consistent with the recent reports from Dube et al., Maqbool et al., Ranjan et al., Goel et al., (2012) and Gupta et al., (2011). Higher mortality was reported by Gupta et al., as 78.94%. Lower mortality was reported by Kant et al., (2015) 15.3% and Patil and Patil et al., (2017) 29.72%. This vast difference in the mortality rate may be attributed to the management of the cases by treatment and preventive measures taken and also the associated comorbidities associated with the patients.

The notable strengths of our study are that it was prospectively conducted, with the diagnosis of VAP based on new NHSN guidelines including clinical, radiological and microbiological results. To date, most Indian studies on VAP infections are from a laboratory-based perspective or considering CPIS scoring system.

This study highlights the need for urgent infection control, planning, as well as multidisciplinary team participation to combat VAP. This includes implementing measures such as education, increased awareness of hand hygiene measures, reduction of the duration of mechanical ventilation and use of other VAP bundles, all of which have been proven to reduce the risk of VAP infections.

Regarding limitations of this study, Findings emerging out of this study may not be generalized as a single centre study limits the generalizability of the findings to other regions of the country. More studies with bigger sample size are warranted.

In conclusion, the findings showed VAP as a problem in the ICU setting, with high percentage of gram negative pathogens and high mortality. Further, to have a comprehensive pan-India picture, multicentric studies with high number of patient population need to be initiated. Majority of these are caused by highly resistant strains and also the frequency of specific pathogens causing VAP may vary by hospital, patient population, and exposure to antibiotics, type of ICU patients and changes over time, emphasizing the need for timely local surveillance data. Adherence to the best practices standards of hospital infection control requires an interdisciplinary team of clinical microbiologists, physicians and hospital infection control nurses, to collectively manage these patients.

References

1. Davis K A. Ventilator-associated pneumonia: a review. J Intensive Care Med. 2006; 21:211-26.
2. Torres A, Ferrer M, Badia JR. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin Infect Dis 2010; 51Suppl 1:S48-53.
3. Masih SM, Goel S, Singh A, Tank R, Khichi SK, Singh S. Incidence and risk factors associated with development of ventilator- associated pneumonia from a tertiary care center of northern India. Int J Res Med Sci. 2016; 4: 1692-7.
4. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: A prospective case control study. Crit Care Med 2001; 29: 2303-9.
5. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the
critically ill patient. The Canadian critical trials group. Am J Respir Crit Care Med 1999; 159: 1249-56.
6. Cook D, De Jonghe B, Brochard L, Brun-Buisson C. Influence of airway management on ventilator-associated pneumonia: Evidence from randomized trials. JAMA 1998; 279: 781-7
7. Quenot JP, Ladoire S, Devoucoux F, Doise JM, Cailliod R, Cunin N, et al. Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia. Crit Care Med 2007; 35: 2031-6.
8. National Healthcare Safety Network (NHSN) Patient Safety Component Manual chapter 10: ventilator associated event (VAE)
9. Colle JG, Fraser AG, Marmion BP, Simmons A. Mackie & McCartney Practical Medical Microbiology: staining methods 14th ed. New Delhi: Reed Elsevier India Private Limited; 2016. p.793-812.
10. Mackie TJ and McCartney JE (1996) Practical medical microbiology, 14th edition. New York: Churchill Livingstone 978p.
11. Debaprasad Mohanty, Sidharth Sraban Routray, Debasis Mishra, Abhilas Das. Ventilator associated pneumonia in an ICU of a tertiary care hospital in India. International Journal of Contemporary Medical Research 2016;3(4):1046-1049.
12. Gupta A, Agrawal A, Mehrotra S, Singh A, Malik S, Khanna A. Incidence, risk stratification, antibiogram of pathogens isolated and clinical outcome of ventilator associated pneumonia. Indian J Crit Care Med 2011; 15: 96-101.
13. A. Abdelrazik Othman, M. Salah Abdelazim. Ventilator-associated pneumonia in adult intensive care unit prevalence and complications. The Egyptian Journal of Critical Care Medicine 5 (2017) 61–63
14. Ranjan N, Chaudhary U, Chaudhry D, Ranjan KP. Ventilator-associated pneumonia in a tertiary care Intensive Care Unit: Analysis of incidence, risk factors and mortality. Indian J Crit Care Med. 2014;18:200–4
15. Deshmukh B, Kadam S, Thirumugam M, Rajesh K. Clinical study of ventilator-associated pneumonia in tertiary care hospital, Kolhapur, Maharashtra, India. Int J Res Med Sci 2017; 5: 2207-11.
16. Dr. Vinit Garg, Dr. (Col) V.R.R. Chari, Dr. Arnab Paul, Dr. BhoomiRaval, Dr. SoumyanathMaiti, A Study of Ventilator Associated Pneumonia (VAP) in Intensive Care Unit (ICU) setting, Indian Journal of Applied Research, Volume 7(1) JANUARY 2017.
17. SarojGolia, Sangeetha K T, Vasudha C L, Microbial profile of Early and late onset VAP, journal of clinical and diagnostic research ,2013,7(11):2462-2466.
18. Usman SM, James PM, Rashmi M. Clinical and microbiological facets of ventilator associated pneumonia in the main stream with a practical contact. Int J Res Med Sci 2014; 2: 239-45.
19. Dube M, Goswami S, Singh A, Raju BM, Dube P, Bhatia GC. Pattern and incidence of ventilator associated pneumonia among mechanically ventilated patients. Int J Adv Med 2018; 5: 442-5.
20. Maqbool M, Shabir A, Naqash H, Amin A, Koul RK, Shah PA. Ventilator Associated Pneumonia-Incidence and Outcome in Adults in Medical Intensive Care Unit of a Tertiary Care Hospital of North India. Int J Sci Stud 2017; 4(10): 73-76.
21. Mathai AS, Phillips A, Isaac R.
Ventilator associated pneumonia: A persistent healthcare problem in Indian Intensive Care Units! Lung India 2016; 33: 512-6.

22. Ranjan N, Chaudhary U, Chaudhry D, Ranjan KP. Ventilator-associated pneumonia in a tertiary care Intensive Care Unit: Analysis of incidence, risk factors and mortality. Indian J Crit Care Med. 2014;18:200–4

23. Masih SM, Goel S, Singh A, Tank R, Khichi SK, Singh S. Incidence and risk factors associated with development of ventilator-associated pneumonia from a tertiary care center of northern India. Int J Res Med Sci 2016; 4: 1692-7.

24. Husain Shabbir Ali, Fahmi Yousef Khan, Saibu George, Nissar Shaikh, and Jameela Al-Ajmi, “Epidemiology and Outcome of Ventilator-Associated Pneumonia in a Heterogeneous ICU Population in Qatar,” BioMed Research International, vol. 2016, Article ID 8231787, 8 pages,

25. Goel V, Hogade SA, Karadesai SG.

26. Gupta A, Agrawal A, Mehrotra S, Singh A, Malik S, Khanna A. Incidence, risk stratification, antibiogram of pathogens isolated and clinical outcome of ventilator associated pneumonia. Indian J Crit Care Med 2011; 15: 96-101.

27. Kant R, Dua R, Beg MA, Chanda R, Gambhir IS, Barnwal S. Incidence, microbiological profile and early outcomes of ventilator associated pneumonia in elderly in a Tertiary Care Hospital in India. Afr J Med Health Sci 2015; 14: 66-9.

28. Patil HV, Patil VC. Incidence, bacteriology, and clinical outcome of ventilator-associated pneumonia at tertiary care hospital. J Nat ScBiol Med 2017; 8: 46-55.

How to cite this article:

Sadiya Fatima, S. Rajeshwar Rao, V.V. Shailaja and Nagamani, K. 2019. Finding the Incidence of Ventilator Associated Pneumonia by Recent NHSN Guidelines and Its Bacteriological Profile: A Study Conducted in a Tertiary Care Hospital in Southern India. Int.J.Curr.Microbiol.App.Sci. 8(10): 2080-2089. doi: https://doi.org/10.20546/ijcemas.2019.810.242